Illumina (NASDAQ:ILMN) PT Raised to $200.00

Illumina (NASDAQ:ILMN) had its price target boosted by Leerink Partners from $160.00 to $200.00 in a report published on Thursday, Benzinga reports. They currently have an outperform rating on the life sciences company’s stock.

Several other analysts also recently weighed in on ILMN. Daiwa Capital Markets upgraded Illumina from a “neutral” rating to a “buy” rating and upped their price target for the stock from $120.00 to $154.00 in a research note on Friday, August 16th. Barclays increased their target price on Illumina from $125.00 to $135.00 and gave the stock an “equal weight” rating in a research note on Tuesday, October 15th. Royal Bank of Canada restated an “outperform” rating and set a $252.00 price target on shares of Illumina in a report on Thursday, October 10th. Scotiabank dropped their price target on shares of Illumina from $176.00 to $164.00 and set a “sector outperform” rating on the stock in a research note on Thursday, August 15th. Finally, Daiwa America upgraded Illumina to a “strong-buy” rating in a research note on Friday, August 16th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $154.33.

Illumina Stock Performance

Shares of Illumina stock opened at $146.07 on Thursday. Illumina has a 12 month low of $89.00 and a 12 month high of $151.40. The firm has a market capitalization of $23.27 billion, a P/E ratio of -17.92 and a beta of 1.15. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 1.04. The business has a fifty day simple moving average of $132.73 and a two-hundred day simple moving average of $121.10.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Tuesday, August 6th. The life sciences company reported $0.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.24. Illumina had a negative net margin of 68.73% and a positive return on equity of 3.08%. The company had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.09 billion. During the same period last year, the business earned $0.32 EPS. Illumina’s quarterly revenue was down 5.4% compared to the same quarter last year. On average, equities analysts forecast that Illumina will post 3.63 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Illumina

A number of institutional investors have recently bought and sold shares of the stock. Mitsubishi UFJ Asset Management UK Ltd. purchased a new stake in shares of Illumina in the third quarter worth $782,000. Raymond James & Associates boosted its holdings in Illumina by 39.6% in the 3rd quarter. Raymond James & Associates now owns 441,182 shares of the life sciences company’s stock worth $57,535,000 after buying an additional 125,073 shares during the period. Claro Advisors LLC bought a new stake in Illumina during the third quarter valued at about $1,275,000. Sumitomo Mitsui DS Asset Management Company Ltd lifted its position in shares of Illumina by 28.3% in the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 15,370 shares of the life sciences company’s stock valued at $2,004,000 after acquiring an additional 3,393 shares in the last quarter. Finally, nVerses Capital LLC bought a new position in shares of Illumina in the third quarter worth about $65,000. 89.42% of the stock is owned by institutional investors.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.